1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Small interfering RNA (siRNA) Therapeutics- Competitive Landscape, Technology and Pipeline Insights, 2016

The Report, “Small interfering RNA (siRNA) Therapeutics- Competitive Landscape, Technology and Pipeline Insights, 2016” depicts the current pipeline scenario of siRNA therapies under development. Many targets which were difficult to reach by traditional small-molecule and protein have been identified by therapeutics based on RNA interference (RNAi). RNA interference (RNAi), a process in recovery Phase, is still keeping the expectations of the many mid Pharma companies at a higher end with blockbuster deals and adequate delivery technologies.

This report analysis the current frontrunners in siRNA therapies with leading technologies and major acquisitions and deals seen in past 3 years. Report highlights the 16 different types of technologies that have been used lately to enhance the siRNA development in different stages of development.

There are 15+ active companies dealing with 85+ siRNA therapies. Mostly siRNA is being studied for oncology area with 27 siRNA therapies under development by major pharma companies followed by 14 therapies for infectious diseases and 8 siRNA therapies in Ophthalmology. Currently 23 siRNA are in clinical stage of development with many mid-stage products.

Scope:

- Coverage of global siRNA therapies under development across the globe
- Competitive landscape of investigational products for key players and key therapy areas
- The new siRNA report includes emerging technologies, drivers, barriers and eminent therapy areas focused by major companies.
- Detailed information on product description and related stage of development, the mode of therapy, mechanism of action, development partner and technology information.
- Report has highlighted the major collaborations, deals and acquisitions done by pharma companies to enrich their siRNA pipeline.
- Report analyzes the different emerging delivery technologies by companies and products under development.

Reason to Buy

- The siRNA report covers complete Pipeline intelligence and understanding over therapeutics development for siRNA.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for siRNA
- The siRNA report helps to develop a better understanding of the emerging technologies by the recent acquisitions which are driving the siRNA market
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding siRNA pipeline in-depth
- Identifying the upcoming leaders in the siRNA market in the coming year

Table Of Contents

Small interfering RNA (siRNA) Therapeutics- Competitive Landscape, Technology and Pipeline Insights, 2016
Table of contents:
Executive Summary
Small interfering RNA (siRNA) Therapeutics Overview
Introduction
Historical Development:
siRNA: Mode of Action
siRNA Technology andDelivery methods
SiRNA and its Applications in Gene Silencing:
Commercial Assessment
Drivers:
Barriers:
siRNA Therapeutics: Technology Analysis
siRNA Technology and Companies Current Scenario
Companies and Technologies
siRNA Technologies and Products
siRNA Therapeutics: Collaborations Analysis
siRNA Theraputics Collaborations and Deals
siRNA Therapeutics Licensing Deals:
siRNA Therapeutics Acquisition Deals
siRNA Therapeutics: Pipeline Analysis
siRNA Theraputics Therapy Area Analysis
siRNA Therpeutics Clinical Trials Analysis
siRNA Therapeutics andUSFDA/EMA Designations
Pipeline Overview
Last Stage Products (Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre-Clinical and Discovery Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Discontinued Products
Dormant Products
Companies involved in Therapeutics Development
Appendix
Methodology
Consulting Services
About DelveInsight
Contact Us
Disclaimer

List of tables:

Table 1: siRNA Technology with delivery methods, 2016
Table 2: siRNA therapeutics collaboration and deal value, 2016
Table 3: siRNA therapeutics Technology Licensing Technology Licensing by Year, 2016
Table 4: siRNA therapeutics acquisition and deal year, 2016
Table 5: Number of Products under Development for Small interfering RNA (siRNA) Therapeutics, 2016
Table 6: Number of Products under Development by Companies, 2016
Table 7: Last Stage Products (Phase III), 2016
Table 8: Mid Stage Products (Phase II), 2016
Table 9: Early Stage Products (Phase I and IND), 2016
Table 10: Pre-Clinical and Discovery Products, 2016
Table 11: Assessment by Monotherapy Products, 2016
Table 12: Assessment by Route of Administration, 2016
Table 13: Assessment by Stage and Route of Administration, 2016
Table 14: Discontinued Products, 2016
Table 15: Dormant Products, 2016

List of figures:

Figure 1: Number of technology associated with the companies, 2016
Figure 3: Number of collaborations with year, 2016
Figure 4: Number of products by therapy area, 2016
Figure 5: Number of products by therapy area and Phases, 2016
Figure 6: Number of products with ongoing and completed clinical trials, 2016
Figure 7: Number of products in clinical trials with companies, 2016
Figure 8: Number of products with designations, 2016
Figure 9: Number of Products under Development for Small interfering RNA (siRNA) Therapeutics, 2016
Figure 10: Last Stage Products (Phase III), 2016
Figure 11: Mid Stage Products (Phase II), 2016
Figure 12: Early Stage Products (Phase I and IND), 2016
Figure 13: Pre-Clinical and Discovery Products, 2016
Figure 14: Assessment by Monotherapy Products, 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

  • $ 6995
  • Industry report
  • January 2017
  • by GBI Research

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation Summary Melanoma is a type of cancer that begins in the ...

Breakthrough Therapies: Market Dynamics and Investment Opportunities

Breakthrough Therapies: Market Dynamics and Investment Opportunities

  • $ 6650
  • Industry report
  • January 2017
  • by BCC Research

Use this report to: - Analyze the challenges and opportunities of developing breakthrough therapies, compare difference fast track drug development approaches and the potential risk and rewards of gaining ...

Alpha Mannosidosis Market and Enzyme Replacement Therapy - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

Alpha Mannosidosis Market and Enzyme Replacement Therapy - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Alpha Mannosidosis Market: Overview With increase in the incidence of alpha mannosidosis worldwide the market for treatment is expected to grow in coming years. Alpha Mannosidosis is a rare inherited ...


Download Unlimited Documents from Trusted Public Sources

Hepatitis Statistics and Therapy Market in the UK

  • March 2017
    10 pages
  • Hepatitis  

    Therapy  

    Antiviral  

  • United Kingdom  

View report >

Opioid Market in the US

  • March 2017
    13 pages
  • Opioid  

  • United States  

View report >

Glucagon Like Peptide 1 Receptor Activator Market

  • March 2017
    3 pages
  • Glucagon Like P...  

    Antidiabetics  

    Cardiology  

View report >

Related Market Segments :

Therapy

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.